Australian research has led to clinical trials of a drug that could provide a painless and non-destructive way to treat blindness in diabetics.
The University of Melbourne-led pre-clinical research prompted the world-wide, multi-centre clinical trial following the announcement of their results at an international conference last year.
The drug blocks a crucial pathway whose end products cause blindness and eye damage in diabetics, the leading cause of new blindness in adults around the world. The trial will begin later this year. The research team’s success also caught the attention of funding agencies. The US-based Juvenile Diabetes Research Foundation (JDRF), the world’s leading non-profit, non-governmental funder of diabetes research and the National Health and Medical Research Council (NHMRC) have granted the University of Melbourne team $4.7 million in funding over five years. The funds will help refine their understanding of the chemical pathways that lead to blindness (diabetic retinopathy) and kidney failure (diabetic
nephropathy) in diabetics and to find new drugs to combat the disease.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!